Volume 1 · Issue 5

Neurodegeneration & the Aging Brain

From cognitive reserve to longitudinal biomarkers, this issue examines the progression of neurodegenerative conditions and the evidence used to distinguish aging from disease.

100 Creative Commons readings · Paulina Valenzuela, MD, Editor-in-Chief

Issue 5 · Reading list

Explore the research

Download issue catalog

100 readings · Page 3 of 5

  1. ALS and frontotemporal degeneration · CC BY 4.0

    Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology.

    Wouter van Rheenen, Rick A A van der Spek, Mark K Bakker, Joke J F A van Vugt et al.

    Nature genetics · 2021

    Original article
  2. ALS and frontotemporal degeneration · CC BY 4.0

    Epidemiology of amyotrophic lateral sclerosis: an update of recent literature.

    Elisa Longinetti, Fang Fang

    Current opinion in neurology · 2019

    Original article
  3. ALS and frontotemporal degeneration · CC BY 4.0

    Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia.

    Jonathan D Rohrer, Ione O C Woollacott, Katrina M Dick, Emilie Brotherhood et al.

    Neurology · 2016

    Original article
  4. ALS and frontotemporal degeneration · CC BY 4.0

    First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound.

    Agessandro Abrahao, Ying Meng, Maheleth Llinas, Yuexi Huang et al.

    Nature communications · 2019

    Original article
  5. ALS and frontotemporal degeneration · CC BY 4.0

    The role of TDP-43 mislocalization in amyotrophic lateral sclerosis.

    Terry R Suk, Maxime W C Rousseaux

    Molecular neurodegeneration · 2020

    Original article
  6. ALS and frontotemporal degeneration · CC BY 4.0

    Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging.

    B Ghetti, A L Oblak, B F Boeve, K A Johnson et al.

    Neuropathology and applied neurobiology · 2015

    Original article
  7. ALS and frontotemporal degeneration · CC BY 4.0

    An update on genetic frontotemporal dementia.

    Caroline V Greaves, Jonathan D Rohrer

    Journal of neurology · 2019

    Original article
  8. ALS and frontotemporal degeneration · CC BY 4.0

    Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.

    Xi Chen, Yang Hu, Zongze Cao, Qingshan Liu et al.

    Frontiers in immunology · 2018

    Original article
  9. ALS and frontotemporal degeneration · CC BY 3.0

    Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion.

    Adrian J Waite, Dirk Bäumer, Simon East, James Neal et al.

    Neurobiology of aging · 2014

    Original article
  10. ALS and frontotemporal degeneration · CC BY 4.0

    Projected increase in amyotrophic lateral sclerosis from 2015 to 2040.

    Karissa C Arthur, Andrea Calvo, T Ryan Price, Joshua T Geiger et al.

    Nature communications · 2016

    Original article
  11. Original article
  12. ALS and frontotemporal degeneration · CC BY 4.0

    Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications.

    Jia Liu, Fei Wang

    Frontiers in immunology · 2017

    Original article
  13. ALS and frontotemporal degeneration · CC BY 4.0

    Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.

    Vlad A. Korben, Alexander K Lyashchenko, Beatriz Blanco-Redondo, Paymaan Jafar-Nejad et al.

    Nature medicine · 2022

    Original article
  14. ALS and frontotemporal degeneration · CC BY 4.0

    Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis.

    Jik Nijssen, Laura H Comley, Eva Hedlund

    Acta neuropathologica · 2017

    Original article
  15. ALS and frontotemporal degeneration · CC BY 4.0

    PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia.

    Helois Radford, Julie A Moreno, Nicholas Verity, Mark Halliday et al.

    Acta neuropathologica · 2015

    Original article
  16. ALS and frontotemporal degeneration · CC BY 4.0

    CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia.

    Kelly L Williams, Simon Topp, Shu Yang, Bradley Smith et al.

    Nature communications · 2016

    Original article
  17. ALS and frontotemporal degeneration · CC BY 4.0

    Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models.

    M Catarina Silva, Fleur M Ferguson, Quan Cai, Katherine A Donovan et al.

    eLife · 2019

    Original article
  18. ALS and frontotemporal degeneration · CC BY 4.0

    Neurofilament light chain: a biomarker for genetic frontotemporal dementia.

    Lieke H Meeter, Elise G Dopper, Lize C Jiskoot, Raquel Sanchez-Valle et al.

    Annals of clinical and translational neurology · 2016

    Original article
  19. ALS and frontotemporal degeneration · CC BY 4.0

    Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.

    Ton Fang, Ahmad Al Khleifat, Jacques-Henri Meurgey, Ashley Jones et al.

    The Lancet. Neurology · 2018

    Original article
  20. ALS and frontotemporal degeneration · CC BY 4.0

    Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

    Federico Verde, Markus Otto, Vincenzo Silani

    Frontiers in neuroscience · 2021

    Original article